AI Insight
A pediatric medical center implemented a value-based care program for children with type 1 diabetes, combining infrastructure funding with performance-based payments tied to clinical outcomes and remote monitoring. Over four years (2021-2025), the program enrolled 786 patients and showed substantial improvements: median HbA1c decreased from 8.6% to 7.9%, the percentage with poorly controlled diabetes (HbA1c >9%) dropped from 41.1% to 27.6%, and emergency admissions for diabetic ketoacidosis decreased from 9.1% to 5.6%. Hospital admissions and emergency department visits also decreased by approximately 30-40%.
Why it matters
This model demonstrates that financial incentives tied to clinical outcomes can improve diabetes management in children while reducing costly emergency care. If validated through peer review and replicated at other centers, this approach could provide a framework for managing other chronic pediatric conditions within value-based payment systems.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Objective: Pediatric specialty value-based care (VBC) for chronic conditions remains under-described. We describe the design and early performance of a data-driven population health model for pediatric type 1 diabetes within a specialty VBC program. Research Design and Methods: Descriptive evaluation at a single academic pediatric medical center and clinically integrated network, 2021-2025, with formal VBC operation beginning in 2024. Participants were children and adolescents with type 1 diabetes attributed through commercial and Medicaid value-based agreements (n=786 in 2025). The program paired infrastructure funding with performance-dependent payments tied to clinical quality and utilization measures, supported by remote monitoring and care management. Measures: percentage receiving the chronic care intervention, population median HbA1c, percentage with HbA1c >9% (75 mmol/mol), percentage with [≥]1 diabetic ketoacidosis (DKA) admission, and inpatient and emergency department (ED) visit rates per 1,000/month. Results: From 2021 to 2025, median HbA1c decreased from 8.6% (70 mmol/mol) to 7.9% (63 mmol/mol), HbA1c >9% (75 mmol/mol) decreased from 41.1% to 27.6%, and [≥]1 DKA admission decreased from 9.1% to 5.6%. Inpatient admissions per 1,000/month decreased from 11.2 to 7.4 and ED visits from 10.0 to 7.6. The program met 3 of 6 targets in 2024 and all 6 in 2025. Conclusions: Pairing infrastructure funding with performance-dependent payments was feasible and associated with sustained improvements in glycemic control and reduced acute care utilization. Further multi-site evaluation is needed to determine impact, generalizability, and sustainability.
Source: A Data-Driven Pediatric Type 1 Diabetes Population Health Model Within Specialty Value-Based Care